Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Radnostix, Inc. Reports FY2026 2nd Quarter and Six Months Results - Completes Execution of FDA 483 & Recall Actions, Restores Capsule Inventory, Completes Lucerno Dynamics Asset Acquisition

IDAHO FALLS, Idaho, Aug. 13, 2026 /PRNewswire/ -- Radnostix, Inc. (formerly International Isotopes Inc.) (OTCQB: INIS) ("Radnostix" or the "Company"), a manufacturer of radioisotope-focused technologies for medical, industrial, and research applications, today announced its financial results for the second quarter and six months ended June 30, 2026 and the filing of its Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission. Second Quarter and First Half 2026 Financial and Operational Summary Total revenue for the three months ended June 30, 2026 was $2.67 million, a 27% decrease from $3.66 million in the prior-year period.